1. Treatment of Travelers’ Diarrhea: Randomized Trial Comparing Rifaximin, Rifaximin Plus Loperamide, and Loperamide Alone 
Herbert L. Dupont, Zhi–Dong Jiang, Jaime Belkind–Gerson, Pablo C. Okhuysen, Charles D. Ericsson, Shi Ke, David B. Huang, Margaret W. Dupont, Javier A. Adachi, F. Javier De La Cabada, David N. Taylor, Sridvya Jaini, Francisco Martinez Sandoval 
Clinical Gastroenterology and Hepatology 
Volume 5, Issue 4, Pages (April 2007)
DOI: /j.cgh
Copyright © 2007 AGA Institute Terms and Conditions

2. Figure 1
Duration of diarrhea after initiation of treatment. TLUS, P = for median and P = for mean, comparing rifaximin-containing treatments with loperamide alone.
Clinical Gastroenterology and Hepatology 2007 5, DOI: ( /j.cgh )
Copyright © 2007 AGA Institute Terms and Conditions

3. Figure 2
Number of unformed stools passed during the first 72 hours of treatment. P = .0024, P = .0076, and P = .0011, comparing rifaximin, rifaximin-loperamide, and loperamide treatment groups at 0–24 hours, >24–48 hours, and >48–72 hours, respectively. A subgroup analysis showed significant differences between rifaximin and rifaximin-loperamide treatments at 0–24 hours (P = .0026) and >24–48 hours (P = .011). The mean number of total unformed stools passed during the study was lower with rifaximin-loperamide (3.99 ± 4.28) compared with rifaximin (6.23 ± 6.90; P = .004) or loperamide (6.72 ± 6.93; P = .002) alone.
Clinical Gastroenterology and Hepatology 2007 5, DOI: ( /j.cgh )
Copyright © 2007 AGA Institute Terms and Conditions

4. Figure 3
Patients’ global assessment of complete wellness. Patients completed a daily diary card that was reviewed clinically until wellness was achieved. A significant difference between rifaximin, rifaximin-loperamide, and loperamide treatment groups was observed at day 1 (*P = .014), day 2 (#P = .016), day 3 (‡P = .01), and day 4 (§P < .0001). A subgroup analysis showed a significant difference in the rate of global assessment of wellness between the rifaximin and rifaximin-loperamide treatment groups for day 1 (∥P = .0047) and day 2 (¶P = .0498).
Clinical Gastroenterology and Hepatology 2007 5, DOI: ( /j.cgh )
Copyright © 2007 AGA Institute Terms and Conditions